Combination of progesterone receptor antagonist to an agonist and an antagonist of luteinizing Hormone Releasing Hormone for use in BRCA mediated Diseases

摘要

Pharmaceutical combination of progesterone receptor antagonist 11beta - (4-acetylphenyl) - 17alfa 17beta hydroxy - (1,1,2,2,2 - pentafluoroetil) - estra - 4.9 - dien - 3-one, or a derivative or an Analogue thereof acceptable for pharmaceutical use together with at least one Hormone agonist or antagonist li Beradora luteinizing HormoneAnd the use of this Combination for prophylaxis and Treatment of diseases mediated by BRCA1 or BRCA2.Agonists and antagonists of the liberadorade Hormone luteinizing hormone that can be combined with the compound 11beta - (4-acetylphenyl) - 17alfa 17beta hydroxy - (1,1,2,2,2 - pentafluoroetil) - estra - 4.9 - dien - 3-one are, for example, gonadorelin, buserelin, goserelin, Triptorelin, nafarelin, slip Orelina, histrelin, Antide, ramorelix, cetrorelix, antarelix, org30850, abarelix,And leuprolina ganirelix.Claim 1: a Pharmaceutical Combination according to claim 1, wherein the combination comprendeel progesterone receptor antagonist 11beta - (4 - acetyl phenyl) - 17alfa 17beta hydroxy - (1,1,2,2,2 - pentafluoroetil) - estra - 4.9 - dien - 3-one, an agonist or an antago Nista of luteinizing Hormone Releasing Hormone and an agent with actividadfarmacologica.Claim 7: a Pharmaceutical Combination according to claim 8, wherein the agent with pharmacological activity is a cytotoxic Agent.Claim 1: use the combination according to Lasreivindicaciones 1 to 10, wherein is like medicine for prophylaxis or treatment of breast cancer mediated by BRCA1 or BRCA2, ovarian cancer, endometrial cancer, gastric cancer, cancer colorrecta L, laendometriosis, myeloma, Myoma and meningioma.